Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human LRP5 Anticorps:
anti-Mouse (Murine) LRP5 Anticorps:
anti-Rat (Rattus) LRP5 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Polyclonal LRP5 Primary Antibody pour WB - ABIN127323
Del Valle-Pérez, Arqués, Vinyoles, de Herreros, Duñach: Coordinated action of CK1 isoforms in canonical Wnt signaling. dans Molecular and cellular biology 2011
Show all 2 Pubmed References
Human Monoclonal LRP5 Primary Antibody pour FACS, ELISA - ABIN969535
Urano, Shiraki, Usui, Sasaki, Ouchi, Inoue: A1330V variant of the low-density lipoprotein receptor-related protein 5 (LRP5) gene decreases Wnt signaling and affects the total body bone mineral density in Japanese women. dans Endocrine journal 2009
Show all 2 Pubmed References
Human Monoclonal LRP5 Primary Antibody pour ELISA, WB - ABIN561692
Badders, Goel, Clark, Klos, Kim, Bafico, Lindvall, Williams, Alexander: The Wnt receptor, Lrp5, is expressed by mouse mammary stem cells and is required to maintain the basal lineage. dans PLoS ONE 2009
Human Monoclonal LRP5 Primary Antibody pour ELISA, WB - ABIN517568
Kim, Goel, Alexander: Differentiation generates paracrine cell pairs that maintain basaloid mouse mammary tumors: proof of concept. dans PLoS ONE 2011
The extracellular domains of Lrp5/6 behave as physiologically relevant inhibitors of noncanonical Wnt (Montrer WNT2 Anticorps) signaling during Xenopus and mouse development in vivo.
Data show that in zebrafish, lrp5 also controls cell migration during early morphogenetic processes and contributes to shaping the craniofacial skeleton.
VAP1 cleaved the extracellular region of LRP5. This cle (Montrer AOC3 Anticorps)avage removes four inhibitory beta-propeller structures, resulting in activation of LRP5/6.
Among the detected mutations, LRP5 accounted for the largest proportion with a mean mutation rate of 16.1% (5/31, 16.1%), followed by NDP (Montrer NDP Anticorps) (3/31, 9.7%), FZD4 (Montrer FZD4 Anticorps) (2/31, 6.5%), TSPAN12 (Montrer TSPAN12 Anticorps) (1/31, 3.2%), and KIF11 (Montrer KIF11 Anticorps) (1/31, 3.2%). All the novel changes were predicted to be pathogenic by a series of bioinformatics analyses.
wild-type and all five mutant LRP5 proteins were assayed for the ability to activate the Norrin (Montrer NDP Anticorps)/beta-catenin (Montrer CTNNB1 Anticorps) pathway by established luciferase reporter assays, and all mutants failed to activate the pathway.
findings revealed an unrecognized role of Caprin-2 (Montrer CAPRIN2 Anticorps) in facilitating LRP5/6 constitutive phosphorylation at G2/M through forming a quaternary complex with CDK14 (Montrer CDK14 Anticorps), Cyclin Y (Montrer CCNY Anticorps), and LRP5/6.
This study did not identify LRP5 polymorphisms as a risk factor for osteoporosis in Thai menopausal women.
We identified four novel LRP5 missense mutations in these FEVR (Montrer NDP Anticorps) families: c.C1042T (p.R348W), c.G1141A (p.D381N), c.C1870T (p.R624W), and c.A4550G (p.Y1517C). All four of these LRP5 mutations led to significant reduction of enzymatic activity with response to NORRIN (Montrer NDP Anticorps). Our findings expand the mutational spectrum of FEVR (Montrer NDP Anticorps) in the Indian population and provide some guidelines in clinical diagnosis.
In this study, the splice site mutation c.2827thorn1G > A found in LRP5 (603506) gene is thought to cause microphthalmia in this family.
A genetic evaluation of the known genes associated with familial exudative vitreoretinopathy (FEVR (Montrer NDP Anticorps)) revealed a novel variant in the LRP5 gene that co-segregated with the phenotype in the family.
Meta-analysis indicates that the LRP5 Ala1330Val polymorphism may not be correlated with fracture susceptibility.
Independently or combined with APOE (Montrer APOE Anticorps), LRP5 polymorphisms may lead to dyslipidemia and are associated with generalized aggressive periodontitis. Dyslipidemia may be a risk indicator for generalized aggressive periodontitis in the Chinese population. Furthermore, two LRP5 polymorphisms (rs682429 and rs312016) might be useful for identifying subjects at higher risk of generalized aggressive periodontitis.
Lrp5(-/-) mice displayed significantly delayed retinal vascular development, absence of deep layer retinal vessels, leading to increased levels of vascular endothelial growth factor and subsequent pathologic glomeruloid vessels, as well as decreased inner retinal visual function.
A mouse LRP5 ectodomain recombinant was cleaved by VAP1 (Montrer AOC3 Anticorps), creating a peptide, VAHLTGIHAVEE, detected by mass spectrometric analysis of the 140-kDa fragment, suggesting that the sessile bond by VAP1 (Montrer AOC3 Anticorps) is Glu1206-Val1207.
we revealed miR (Montrer MLXIP Anticorps)-375-3p negatively regulated osteogenesis by targeting LRP5 and beta-catenin (Montrer CTNNB1 Anticorps)
lung myeloid cells are responsive to Lrp5/beta-catenin (Montrer CTNNB1 Anticorps) signaling, leading to differentiation of an alveolar macrophage subtype that antagonizes the resolution of lung fibrosis.
LRP5 is a novel anti-inflammatory macrophage marker that positively regulates migration, phagocytosis, lipid uptake and metabolism.
These results revealed a new role of the canonical Lrp5/6-beta-catenin (Montrer CTNNB1 Anticorps) pathway in regulating the morphogenesis of the cerebellum during postnatal development.
LRP5 function in mice causes retinal hypovascularization during development as well as retinal neovascularization in adulthood with disorganized and leaky vessels.
Lrp5 is required for glucose uptake, and glucose uptake regulates the growth rate of mammary epithelial cells in culture.
Data show that LDL receptor (Montrer LDLR Anticorps)-related protein 5 (Montrer CAPS Anticorps) (LRP5) gain-of-function mutations do not activate beta-catenin (Montrer CTNNB1 Anticorps) signaling in osteoblasts.
These in vivo data support in vitro studies regarding the mechanism of HBM-causing mutations, and imply that HBM LRP5 receptors differ in their relative sensitivity to inhibition by SOST (Montrer SOST Anticorps) and DKK1 (Montrer DKK1 Anticorps).
This gene encodes a transmembrane low-density lipoprotein receptor that binds and internalizes ligands in the process of receptor-mediated endocytosis. This protein also acts as a co-receptor with Frizzled protein family members for transducing signals by Wnt proteins and was originally cloned on the basis of its association with type 1 diabetes mellitus in humans. This protein plays a key role in skeletal homeostasis and many bone density related diseases are caused by mutations in this gene. Mutations in this gene also cause familial exudative vitreoretinopathy.
Lipoprotein Receptor Related Protein 5
, low density lipoprotein receptor-related protein 5
, low-density lipoprotein receptor-related protein 5
, low-density lipoprotein receptor-related protein 5-like
, low density lipoprotein receptor-related protein 7
, low-density lipoprotein receptor-related protein 7